I switched from injectable to oral semaglutide for travel reasons and the fasting window is proving harder to hold than the injection ever was.
What would genuinely help is knowing how much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly.
Numbers rather than impressions, if you have them.
Short answer first, then the reasoning. Orforglipron is the more interesting oral story because it is not a peptide at all. Being a small molecule it does not need SNAC, does not need the fasting window, and has oral bioavailability in the tens of percent rather than about one.
Dr.PeteFamMed said:Orforglipron is the more interesting oral story because it is not a peptide at all.
Agreeing with Dr.PeteFamMed, and the qualification matters more than the agreement. Worth adding that the tablet is taken daily, so a missed dose costs far less than a missed weekly injection. That is a genuine advantage nobody lists.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsDr.SurgeonPGH said:I switched from injectable to oral semaglutide for travel reasons and the fasting window is proving harder to hold than the injection ever was.
Same position here, arrived at the long way round. The OASIS programme put 50mg oral in the same territory as 2.4mg injectable — around 15% mean weight loss — but it needed a dose 20 times larger to get there because almost none of the tablet is absorbed. The dose numbers are not comparable across routes and quoting them side by side confuses people.
Adding the clinical framing, because it changes how the question reads. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.